during intermittent melphalan-prednisone therapy the area under the plasma concentration-time curve of melphalan increased by an average of 45 % after oral or intravenous administration of the drug in myeloma patients during the initial three courses at six-week intervals .
C0025241
melphalan
C0026764
myeloma